Sign inCreate account

Report workspace

Add to folder
NCT03470961UNKNOWNanonymous

Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study

Sponsor

Source record

Tianjin First Central Hospital

Phase

Source record

Phase 4

Modality

AI-normalized

small molecule

Target

AI-normalized

Polyclonal antibodies targeting T-lymphocytes (Grafalon and Anti-thymocyte globulins)

Indication / condition

AI-normalized

CKD (Chronic Kidney Disease) Stage 5T

Intervention

Source record

Anti-Tlymphocyte Globulins, Anti-Thymocyte Globulins

Related intelligence directories

Indication directory: CKD (Chronic Kidney Disease) Stage 5TModality directory: small moleculeTarget directory: Polyclonal antibodies targeting T-lymphocytes (Grafalon and Anti-thymocyte globulins)

Source & freshness

Source record

NCT ID

NCT03470961

Original source

ClinicalTrials.gov

Source last updated

Mar 20, 2018

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03470961

Title

Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study

Sponsor

Tianjin First Central Hospital

Status

UNKNOWN

Phase

Phase 4

Condition raw

CKD (Chronic Kidney Disease) Stage 5T, Diabetes Mellitus, Simultaneous Pancreas Kidney Transplantation

Condition normalized

CKD (Chronic Kidney Disease) Stage 5T, Diabetes Mellitus, Simultaneous Pancreas Kidney Transplantation

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Polyclonal antibodies targeting T-lymphocytes (Grafalon and Anti-thymocyte globulins)

Target normalized

Polyclonal antibodies targeting T-lymphocytes (Grafalon and Anti-thymocyte globulins)

Interventions

Anti-Tlymphocyte Globulins, Anti-Thymocyte Globulins

Public preview

Source record

The study, sponsored by Tianjin First Central Hospital, aims to evaluate the safety and efficacy of polyclonal antibodies in simultaneous pancreas-kidney transplant recipients. Given the increasing prevalence of diabetes and associated end-stage renal disease, the market for immunosuppressive therapies in transplant patients is significant. The results of this study could position the sponsor favorably in the transplant immunosuppression market, particularly if non-inferiority is demonstrated between Grafalon and ATG. Competitive implications include potential market share against established therapies, contingent on successful outcomes and regulatory approval. Diligence considerations should focus on the safety profile and long-term efficacy of the treatments being compared.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT03470961

Status

UNKNOWN

Phase

Phase 4

Sponsor

Tianjin First Central Hospital

Executive brief

Investment-Ready Snapshot

The study, sponsored by Tianjin First Central Hospital, aims to evaluate the safety and efficacy of polyclonal antibodies in simultaneous pancreas-kidney transplant recipients. Given the increasing prevalence of diabetes and associated end-stage renal disease, the market for immunosuppressive therapies in transplant patients is significant. The results of this study could position the sponsor favorably in the transplant immunosuppression market, particularly if non-inferiority is demonstrated between Grafalon and ATG. Competitive implications include potential market share against established therapies, contingent on successful outcomes and regulatory approval. Diligence considerations should focus on the safety profile and long-term efficacy of the treatments being compared.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 20, 2018
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03470961

Indication

CKD (Chronic Kidney Disease) Stage 5T

Modality

small molecule

Target

Polyclonal antibodies targeting T-lymphocytes (Grafalon and Anti-thymocyte globulins)

Intervention

Anti-Tlymphocyte Globulins, Anti-Thymocyte Globulins

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.